GDTC (CytoMed Therapeutics) Insider Ownership: 9.45 % (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GDTC CytoMed Therapeutics Ltd GDTC
27 GF Score
Price $0.99
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Insider Ownership?

CytoMed Therapeutics GDTC +12.50% 27 Insider Ownership is 9.45 % as of Jul. 25, 2026. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CytoMed Therapeutics's insider ownership is 9.45%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CytoMed Therapeutics's Institutional Ownership is 0.14%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CytoMed Therapeutics's Float Percentage Of Total Shares Outstanding is 29.55%.

CytoMed Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for CytoMed Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics Insider Ownership Chart

CytoMed Therapeutics Historical Data

The historical data trend for CytoMed Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 5.91 5.91 5.81 5.81 5.81 5.81 5.81 5.81 8.58 9.45
GDTC
27GF Score
CytoMed Therapeutics Ltd GDTC
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoMed Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 9.45 % mean?
CytoMed Therapeutics (GDTC) has a Insider Ownership of 9.45 % as of Jul. 25, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on CytoMed Therapeutics and its competitors.
Is CytoMed Therapeutics' Insider Ownership too high?
CytoMed Therapeutics' current Insider Ownership is 9.45 %. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Insider Ownership compare to LEXX and INAB?
CytoMed Therapeutics' Insider Ownership of 9.45 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current Insider Ownership is 9.45 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current Insider Ownership of 9.45 %. The current Insider Ownership is 9.45 %. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current Insider Ownership is 9.45 % as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges F98:Germany
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score

Get the complete analysis for GDTC

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price